
Brian J Davis
Examiner (ID: 17895, Phone: (571)272-0638 , Office: P/1672 )
| Most Active Art Unit | 1621 |
| Art Unit(s) | 1615, 1672, 1614, 1621, 1627, 1612 |
| Total Applications | 2844 |
| Issued Applications | 2304 |
| Pending Applications | 200 |
| Abandoned Applications | 369 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20192170
[patent_doc_number] => 20250268880
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-08-28
[patent_title] => 3-(Hydroxy)-Pyridin-4(1H)-One Compounds and Methods of Making and Using the Same
[patent_app_type] => utility
[patent_app_number] => 19/202501
[patent_app_country] => US
[patent_app_date] => 2025-05-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14069
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19202501
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/202501 | 3-(Hydroxy)-Pyridin-4(1H)-One Compounds and Methods of Making and Using the Same | May 7, 2025 | Pending |
| 18/852937 | CATIONIC LIPID COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Apr 21, 2025 | Pending |
Array
(
[id] => 19816655
[patent_doc_number] => 20250074862
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-03-06
[patent_title] => CRYSTALLINE FORM OF TRIETHYLENETETRAMINE TETRAHYDROCHLORIDE AND ITS PHARMACEUTICAL USE
[patent_app_type] => utility
[patent_app_number] => 18/948050
[patent_app_country] => US
[patent_app_date] => 2024-11-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11630
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 102
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18948050
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/948050 | Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use | Nov 13, 2024 | Issued |
Array
(
[id] => 19792238
[patent_doc_number] => 12233161
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2025-02-25
[patent_title] => Lipids and lipid nanoparticle formulations
[patent_app_type] => utility
[patent_app_number] => 18/669214
[patent_app_country] => US
[patent_app_date] => 2024-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43405
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 136
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18669214
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/669214 | Lipids and lipid nanoparticle formulations | May 19, 2024 | Issued |
Array
(
[id] => 19884095
[patent_doc_number] => 12269787
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2025-04-08
[patent_title] => Method to selectively produce benzalaniline from a Schiff-base reaction involving aniline and benzaldehyde
[patent_app_type] => utility
[patent_app_number] => 18/668526
[patent_app_country] => US
[patent_app_date] => 2024-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 3534
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18668526
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/668526 | Method to selectively produce benzalaniline from a Schiff-base reaction involving aniline and benzaldehyde | May 19, 2024 | Issued |
Array
(
[id] => 19642857
[patent_doc_number] => 20240417377
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-19
[patent_title] => COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING ss-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA
[patent_app_type] => utility
[patent_app_number] => 18/659997
[patent_app_country] => US
[patent_app_date] => 2024-05-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27296
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18659997
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/659997 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING ss-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | May 8, 2024 | Abandoned |
Array
(
[id] => 19921666
[patent_doc_number] => 12295925
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-13
[patent_title] => Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib
[patent_app_type] => utility
[patent_app_number] => 18/648426
[patent_app_country] => US
[patent_app_date] => 2024-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6683
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18648426
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/648426 | Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib | Apr 27, 2024 | Issued |
Array
(
[id] => 19938849
[patent_doc_number] => 12310962
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-27
[patent_title] => Methods and compositions for treating cancer
[patent_app_type] => utility
[patent_app_number] => 18/647511
[patent_app_country] => US
[patent_app_date] => 2024-04-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 7
[patent_no_of_words] => 2350
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 102
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18647511
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/647511 | Methods and compositions for treating cancer | Apr 25, 2024 | Issued |
Array
(
[id] => 19860659
[patent_doc_number] => 20250099445
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-03-27
[patent_title] => METHODS OF TREATMENT OF TUBEROUS SCLEROSIS COMPLEX
[patent_app_type] => utility
[patent_app_number] => 18/641640
[patent_app_country] => US
[patent_app_date] => 2024-04-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12419
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18641640
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/641640 | METHODS OF TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | Apr 21, 2024 | Pending |
Array
(
[id] => 19948335
[patent_doc_number] => 12319682
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-06-03
[patent_title] => Indole and benzimidazole derivatives as dual 5-HT
[patent_app_type] => utility
[patent_app_number] => 18/637083
[patent_app_country] => US
[patent_app_date] => 2024-04-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15489
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18637083
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/637083 | Indole and benzimidazole derivatives as dual 5-HT | Apr 15, 2024 | Issued |
Array
(
[id] => 19448909
[patent_doc_number] => 20240309039
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-19
[patent_title] => PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS
[patent_app_type] => utility
[patent_app_number] => 18/632908
[patent_app_country] => US
[patent_app_date] => 2024-04-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17307
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18632908
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/632908 | PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS | Apr 10, 2024 | Pending |
Array
(
[id] => 19554771
[patent_doc_number] => 20240366563
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-07
[patent_title] => METHODS OF TREATING MALIGNANT LYMPHOPROLIFERATIVE DISORDERS
[patent_app_type] => utility
[patent_app_number] => 18/630283
[patent_app_country] => US
[patent_app_date] => 2024-04-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13406
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 82
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18630283
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/630283 | METHODS OF TREATING MALIGNANT LYMPHOPROLIFERATIVE DISORDERS | Apr 8, 2024 | Abandoned |
Array
(
[id] => 19331218
[patent_doc_number] => 20240245648
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-25
[patent_title] => TREATMENTS WITH NIROGACESTAT
[patent_app_type] => utility
[patent_app_number] => 18/624670
[patent_app_country] => US
[patent_app_date] => 2024-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28383
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18624670
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/624670 | Treatments with nirogacestat | Apr 1, 2024 | Issued |
Array
(
[id] => 19379219
[patent_doc_number] => 20240269089
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-15
[patent_title] => MYRCENE-CONTAINING COMPLEX MIXTURES TARGETING TRPV1
[patent_app_type] => utility
[patent_app_number] => 18/624108
[patent_app_country] => US
[patent_app_date] => 2024-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15241
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 89
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18624108
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/624108 | MYRCENE-CONTAINING COMPLEX MIXTURES TARGETING TRPV1 | Mar 31, 2024 | Pending |
Array
(
[id] => 19299878
[patent_doc_number] => 20240228447
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-11
[patent_title] => SUBSTITUTED NAPHTHYL P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/618110
[patent_app_country] => US
[patent_app_date] => 2024-03-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20120
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 108
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18618110
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/618110 | Substituted naphthyl P38alpha mitogen-activated protein kinase inhibitors | Mar 26, 2024 | Issued |
Array
(
[id] => 19379204
[patent_doc_number] => 20240269074
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-15
[patent_title] => LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 18/617058
[patent_app_country] => US
[patent_app_date] => 2024-03-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 59955
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -63
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18617058
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/617058 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Mar 25, 2024 | Pending |
Array
(
[id] => 19682262
[patent_doc_number] => 20250000807
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-02
[patent_title] => circCDK13-ENRICHED ENGINEERED SMALL EXTRACELLULAR VESICLE (E-sEV), AND PREPARATION METHOD AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/613014
[patent_app_country] => US
[patent_app_date] => 2024-03-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4204
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18613014
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/613014 | circCDK13-ENRICHED ENGINEERED SMALL EXTRACELLULAR VESICLE (E-sEV), AND PREPARATION METHOD AND USE THEREOF | Mar 20, 2024 | Pending |
Array
(
[id] => 19248640
[patent_doc_number] => 20240199627
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => MONOHYDRATE AND CRYSTALLINE FORMS OF 6-[(3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONE
[patent_app_type] => utility
[patent_app_number] => 18/594898
[patent_app_country] => US
[patent_app_date] => 2024-03-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16425
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 7
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18594898
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/594898 | Monohydrate and crystalline forms of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | Mar 3, 2024 | Issued |
Array
(
[id] => 19417197
[patent_doc_number] => 20240293320
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-05
[patent_title] => Mechanism for Bioavailable Delivery of Electrolytes
[patent_app_type] => utility
[patent_app_number] => 18/593290
[patent_app_country] => US
[patent_app_date] => 2024-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6869
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 235
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18593290
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/593290 | Mechanism for Bioavailable Delivery of Electrolytes | Feb 29, 2024 | Pending |
Array
(
[id] => 19543072
[patent_doc_number] => 20240360108
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-31
[patent_title] => SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 18/581307
[patent_app_country] => US
[patent_app_date] => 2024-02-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 116521
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18581307
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/581307 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Feb 18, 2024 | Pending |